Helixgate https://validator.w3.org/feed/docs/rss2.html Home STAT+: After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers Michigan reports first two U.S. deaths in outbreak of cyclospora STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments Evolutionarily Diverse Organisms Switch Genes on Simply and Switch Them off Dynamically Supernus and Indivior merge to create CNS mega-company with 11 approved drugs STAT+: Is there a pharma mega-merger in the making? BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech STAT+: Senate measure would block Trump plan to politicize federal grants, for now STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states Novo’s late-stage IL-6 stumble shakes inflammation space STAT+: BioNTech names Guido Oelkers its new CEO ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets Heart transplants fail if patients get too weak. New program tries inpatient prehab  Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out 5 companies advancing ATTR assets in the wake of Wainua’s fail StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel Spatiotemporal Multiomics Charts Cellular Dynamics of Liver Metastasis Combined Phage Therapy and FMT Reduces Recurrent UTIs and Antibiotic Use in First Human Case Series Replimune melanoma drug wins support of FDA panel Alnylam plunges as earnings deliver ‘one-two punch’ STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing De novo L-(+)-tartaric acid biosynthesis in multi-modular engineered yeasts Ketamine Triggers Sex-Specific Brain Recovery Responses Lilly and Resilience invest $750M in diabetes and obesity drug device supply Novo setback casts doubt on a new way to treat heart disease Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s AbbVie shares pressured as Q2 I&I beat falls below investor expectations Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9% Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs This week in Drug Discovery (27-31 July 2026)  STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma Federal government could improve infectious disease monitoring, says federal government Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail Opinion: What a recent op-ed got wrong about our Covid study Construction of a diverse echinocandin library via combinatorial biosynthesis targeting improved physicochemical properties and bioactivity Capricor’s data clash and a fugitive in the C-suite A Computational Framework for Designing Disordered Proteins at Large Scale Capricor CEO won’t rule out legal action against FDA after negative adcomm Replimune’s twice-rejected melanoma drug prevails in FDA adcomm FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest Microbiota-Derived Metabolite Enhances HIV Therapy in Monkeys